언어 선택
NSP8
NSP8 분자 정보
| 영어 이름 | SARS-CoV-2-3C-like-proteinase | 시판 약물 수 | 7 |
| 임상 약물 수 | 27 | 표적 별명 | Papain-like proteinase，p65 homolog，MPro，SARS-CoV-2 3CLpro，3CL-PRO，GFL，Growth factor-like peptide，Leader protein，Non-structural protein 1，Non-structural protein 10，Non-structural protein 7，Non-structural protein 6，Non-structural protein 4，Non-structural protein 3，Non-structural protein 2，Non-structural protein 11，Non-structural protein 8，Non-structural protein 9，nsp1，nsp10，nsp11，nsp2，nsp3，nsp4，nsp5，nsp6，nsp7，nsp8，nsp9，ORF1a polyprotein，SARS coronavirus main proteinase，Replicase polyprotein 1a，pp1a，PL-PRO，PL2-PRO |
| 최고 연구 개발 단계 | Approved | ||
| 영어 이름 | SARS-CoV-2-3C-like-proteinase |
| 표적 별명 | Papain-like proteinase，p65 homolog，MPro，SARS-CoV-2 3CLpro，3CL-PRO，GFL，Growth factor-like peptide，Leader protein，Non-structural protein 1，Non-structural protein 10，Non-structural protein 7，Non-structural protein 6，Non-structural protein 4，Non-structural protein 3，Non-structural protein 2，Non-structural protein 11，Non-structural protein 8，Non-structural protein 9，nsp1，nsp10，nsp11，nsp2，nsp3，nsp4，nsp5，nsp6，nsp7，nsp8，nsp9，ORF1a polyprotein，SARS coronavirus main proteinase，Replicase polyprotein 1a，pp1a，PL-PRO，PL2-PRO |
| 시판 약물 수 | 7 |
| 임상 약물 수 | 27 |
| 최고 연구 개발 단계 | Approved |
NSP8 제품 목록
- 속성
Protein (1)
- 제품 라이브러리
온라인 (1)
- 종
SARS-CoV-2 (1)
- 태그
His Tag (1)
- 마커
Unconjugated (1)
| 제품 번호 | 종 | 발현 시스템 | 제품 설명 | 단백질 구조 | 순도 | 특성 |
|---|---|---|---|---|---|---|
NS8-C5149 | SARS-CoV-2 | E. coli | SARS-CoV-2 (COVID-19) NSP8 Protein, His Tag |  |  |
총 수량1
- 1
NSP8분자 배경
NSP8, forms a hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, may synthesize substantially longer products than oligonucleotide primers. To ultimately combat the emerging COVID-19 pandemic, it is desired to develop an effective and safe vaccine against this highly contagious disease caused by the SARS-CoV-2 coronavirus. By investigating the entire proteome of SARS-CoV-2, six proteins, including the S protein and five non-structural proteins (nsp3, 3CL-pro, and nsp8-10) were predicted to be adhesins, which are crucial to the viral adhering and host invasion. The S, nsp3, and nsp8 proteins were also predicted by Vaxign-ML to induce high protective antigenicity.
NSP8분자 별명
NSP8,nsp8,Non-structural protein 8
임상 약물 정보
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|
| Ebselen | SPI-1005; SPI-3005; PZ-51; DR-3305 | Phase 3 Clinical | Daiichi Sankyo Co Ltd, Sound Pharmaceuticals Inc | Bipolar Disorder; Cochlear Diseases; Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Depressive Disorder, Treatment-Resistant; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Head and Neck Neoplasms; Hearing Loss; Hearing Loss, Noise-Induced; Lung Neoplasms; Meniere Disease; Neoplasms; Nervous System Diseases; Ototoxicity; Tinnitus | 상세 |
| Secutrelvir | S-892216 | Phase 3 Clinical | Shionogi & Co Ltd | Coronavirus Disease 2019 (COVID-19); Renal Insufficiency | 상세 |
| ibuzatrelvir | PF-07817883; PF-7817883 | Phase 3 Clinical | Pfizer Inc | Coronavirus Disease 2019 (COVID-19) | 상세 |
| Mprosevir | WPV-01 | Phase 3 Clinical | Westlake University | Coronavirus Disease 2019 (COVID-19) | 상세 |
| QLS-1128 | QLS-1128 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Coronavirus Disease 2019 (COVID-19) | 상세 |
| MIR-19 | MIR-19 | Phase 3 Clinical | St. Petersburg Scientific Research Institute of Vaccines and Sera | Coronavirus Disease 2019 (COVID-19) | 상세 |
| Bofutrelvir | FB-2001; DC-402234 | Phase 3 Clinical | Frontier Biotechnologies Inc, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Coronavirus Disease 2019 (COVID-19) | 상세 |
| Nirmatrelvir | PF-07321332 | Phase 3 Clinical | Pfizer As | Coronavirus Disease 2019 (COVID-19); Hepatic Insufficiency; Post-Acute COVID-19 Syndrome | 상세 |
| CDI-988 | CDI988 | Phase 2 Clinical | Cocrystal Pharma Inc | Coronavirus Disease 2019 (COVID-19); Norovirus Infections | 상세 |
| Travatrelvir | 83-0060; TRX-01 | Phase 2 Clinical | Traws Pharma Inc | Coronavirus Disease 2019 (COVID-19) | 상세 |
| Deusitrelvir | SHEN-211; SHEN211 | Phase 2 Clinical | Hubei JKT BioPharma Co Ltd | Coronavirus Disease 2019 (COVID-19) | 상세 |
| HS-10517 | HS-10517; HS10517 | Phase 2 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd | Coronavirus Disease 2019 (COVID-19) | 상세 |
| Zevotrelvir | EDP-235 | Phase 2 Clinical | Enanta Pharmaceuticals Inc | Coronavirus Disease 2019 (COVID-19) | 상세 |
| Tollovir | Phase 2 Clinical | Todos Medical Ltd | Coronavirus Disease 2019 (COVID-19) | 상세 | |
| SNB-011 | SNB-01; SNB-011 | Phase 2 Clinical | Syneurx International (Taiwan) Corp | Coronavirus Disease 2019 (COVID-19) | 상세 |
| Pomotrelvir | PBI-0451 | Phase 1 Clinical | Pardes Biosciences Inc | Coronavirus Disease 2019 (COVID-19) | 상세 |
| CMX-990 | CMX-990; CMX990 | Phase 1 Clinical | The Scripps Research Institute Inc | Coronavirus Disease 2019 (COVID-19) | 상세 |
| WPV-02 | WPV-02; WPV02 | Phase 1 Clinical | Westlake Pharmaceuticals (Hangzhou) Co Ltd | Virus Diseases | 상세 |
| ISM-3312 | ISM-3312 | Phase 1 Clinical | Insilico Medicine Ltd | Coronavirus Disease 2019 (COVID-19) | 상세 |
| Limnetrelvir | ABBV-903 | Phase 1 Clinical | Abbvie Inc | 상세 | |
| SAL-0133 | SAL-0133 | Phase 1 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Coronavirus Disease 2019 (COVID-19) | 상세 |
| SYH-2055 | SYH-2055 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd | Coronavirus Disease 2019 (COVID-19) | 상세 |
| Atilotrelvir | GST-HG171 | Phase 1 Clinical | Fujian Guangsheng Zhonglin Biotechnology Co Ltd | Coronavirus Disease 2019 (COVID-19) | 상세 |
| ALG-097558 | ALG-097558 | Phase 1 Clinical | Aligos Therapeutics Inc, Centre for Drug Design and Discovery, Rega Institute for Medical Research | Coronavirus Disease 2019 (COVID-19) | 상세 |
| ASC11 | ASC-11 | Phase 1 Clinical | Ascletis Pharma Inc | Coronavirus Disease 2019 (COVID-19) | 상세 |
| Lufotrelvir | PF-07304814 | Phase 1 Clinical | Pfizer Inc | Coronavirus Disease 2019 (COVID-19); Virus Diseases | 상세 |
| GS221 | GS-221; GS221 | Clinical | Grand Pharmaceutical （China） Co Ltd | Coronavirus Disease 2019 (COVID-19) | 상세 |
시판 약물 정보
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 가장 빠른 브랜드 이름 | 가장 빠른 승인 국가 | 가장 빠른 적응증 | 가장 빠른 승인 회사 | 가장 빠른 승인 날짜 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|---|---|---|---|---|
| Olgotrelvir | STI-1558; STI1558 | Approved | Texas A&M University | Ovydso, 奥维宁 | Mainland China | Coronavirus Disease 2019 (COVID-19) | Zhejiang Acea Pharmaceutical Co Ltd | 2025-10-28 | Coronavirus Disease 2019 (COVID-19); Pulmonary Disease, Chronic Obstructive | 상세 |
| Atilotrelvir/Ritonavir | Approved | Fujian Guangsheng Zhonglin Biotechnology Co Ltd | 泰中定 | Mainland China | Coronavirus Disease 2019 (COVID-19) | Fujian Guangsheng Zhonglin Biotechnology Co Ltd | 2023-11-23 | Coronavirus Disease 2019 (COVID-19) | 상세 | |
| Simnotrelvir | SIM-0417; SSD-8432; VV-934 | Approved | Jiangsu Simcere Pharmaceutical Co Ltd | Mainland China | Coronavirus Disease 2019 (COVID-19) | Jiangsu Simcere Pharmaceutical Co Ltd | 2023-01-28 | Coronavirus Disease 2019 (COVID-19) | 상세 | |
| Leritrelvir | RAY003; RAY-003; RAY-1216 | Approved | Guangdong Raynovent Biotech Co Ltd | 乐睿灵 | Mainland China | Coronavirus Disease 2019 (COVID-19) | Guangdong Raynovent Biotech Co Ltd | 2023-03-23 | Acute Kidney Injury; Coronavirus Disease 2019 (COVID-19); Hepatic Insufficiency | 상세 |
| Simnotrelvir/Ritonavir | SIM-0417/Ritonavir; SSD-8432 / Ritonavir; SIM-0417 / Ritonavir; VV934 / Ritonavir | Approved | Jiangsu Simcere Pharmaceutical Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Wuhan Institute Of Virology, Chinese Academy Of Sciences | 先诺欣 | Mainland China | Coronavirus Disease 2019 (COVID-19) | Jiangsu Simcere Pharmaceutical Co Ltd | 2023-01-28 | Coronavirus Disease 2019 (COVID-19); Hepatic Insufficiency; Renal Insufficiency | 상세 |
| Ensitrelvir Fumaric Acid | S-217622 | Approved | Hokkaido University, Shionogi & Co Ltd | Xocova | Japan | Coronavirus Disease 2019 (COVID-19) | Shionogi & Co Ltd | 2022-11-22 | Coronavirus Disease 2019 (COVID-19); Hepatic Insufficiency; Post-Acute COVID-19 Syndrome; Renal Insufficiency | 상세 |
| Nirmatrelvir/Ritonavir | Approved | Pfizer Inc | Paxlovid, 瑞派乐 | EU | Coronavirus Disease 2019 (COVID-19) | Pfizer Europe Ma Eeig | 2022-01-28 | Coronavirus Disease 2019 (COVID-19); Immunologic Deficiency Syndromes; Post-Acute COVID-19 Syndrome; Postural Orthostatic Tachycardia Syndrome | 상세 |
- 분자 정보
- 제품 목록
- 시판 약물 정보
- 임상 약물 정보
공유하기:
온라인 메시지
문의하기
전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호